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Age-related macular degeneration (AMD) is a leading
cause of visual impairment worldwide. Aberrant DNA
methylation within the promoter of IL17RC in periph-
eral blood mononuclear cells has recently been
reported in AMD. To validate this association, we
examined DNA methylation of the IL17RC promoter
in peripheral blood. First, we used Illumina Human
Methylation450 Bead Arrays, a widely accepted plat-
form for measuring global DNAmethylation. Second,
methylation status at multiple sites within the IL17RC
promoter was determined by bisulfite pyrosequenc-
ing in two cohorts. Third, a methylation-sensitive
quantitative PCR-based assay was performed on a
subset of samples. In contrast to previous findings,
we did not find evidence of differential methylation
between AMD cases and age-matched controls.
We conclude that hypomethylation within the
IL17RC gene promoter in peripheral blood is not suit-
able for use as a clinical biomarker of AMD. This
study highlights the need for considerable replication
of epigenetic association studies prior to clinical
application.Cell ReINTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of
irreversible loss of central vision in developed countries,
affecting approximately 30–50 million people worldwide (Cole-
man et al., 2008). The disease severely impairs quality of life
(Rung and Lo¨vestam-Adrian, 2013) and is a substantial eco-
nomic burden internationally. AMD is a complex disease
involving an interaction between genetic and environmental
risk factors. Numerous genes that confer a predisposition to
AMD have now been identified, and together these account for
10%–30% of the variability in disease risk (Fritsche et al.,
2013). Strong associations have also been established between
AMD and cigarette smoking (Delcourt et al., 1998, 2011) as well
as, to some degree, sun exposure (Sui et al., 2013), while
increased dietary antioxidants and fish consumption appear to
confer a protective effect (Tan et al., 2009; van Leeuwen et al.,
2005).
The mechanisms underlying the observed interplay of genes
and the environment in the pathogenesis of AMD are poorly
understood; however, cumulative and stable epigenetic variation
represents a plausible and attractive model. Epigenetic modifi-
cation of the human genome is an important mechanism
mediating gene-environment interactions by modulating envi-
ronmental effects on gene expression. For example, cigarette
smoking has been shown to be associated with widespreadports 6, 1527–1535, December 26, 2013 ª2013 The Authors 1527
Figure 1. Methylation of the IL17RC Promoter in Peripheral Blood
from the Michigan AMD-MMAP Cohort as Measured by the Illumina
450K Bead Array at Probe cg19148440
This region corresponds to the previously reported differentially methylated
region in AMD (Wei et al., 2012). The proportion of DNA methylation from
control (red, n = 99) and AMD (blue, n = 199) is plotted for each individual. There
was no statistically significant difference in methylation between the AMD and
control groups.
See also Figure S1 and Table S1.changes in DNA methylation (Lee and Pausova, 2013). Thus,
efforts have been begun to explore the role of epigenetics in
AMD (Hunter et al., 2012; Baird and Wei, 2013).
It is widely accepted that highly expressed genes usually lack
cytosine methylation within CpG-rich ‘‘islands’’ associated with
many promoters; conversely, methylation within these regions
is typically associated with suppression of transcription (Deaton
and Bird, 2011). We have previously described the importance of
DNA methylation in the regulation of retina-specific genes
(Merbs et al., 2012; Oliver et al., 2013;Wan et al., 2013; Nasonkin
et al., 2013). Aberrant CpG island hypermethylation leading to
inactivation of tumor suppressor genes as well abnormal hypo-
methylation resulting in oncogene overexpression is character-
istic of neoplasia (Jiang et al., 2013), including retinoblastoma
(Choy et al., 2002) and uveal melanoma (Maat et al., 2007). Cyto-
sine methylation may also influence the development of other
age-related diseases (Adwan and Zawia, 2013; Miao et al.,
2013), including AMD (Hunter et al., 2012; Wei et al., 2012). How-
ever, conclusive data in the field are scarce, primarily due to the
lack of replication of original association studies. A recent report
suggested that the promoter of the interleukin 17 receptor C
(IL17RC) gene, which encodes a single-pass type I transmem-
brane protein involved in T cell activation (Martin et al., 2011),
is hypomethylated in peripheral blood samples from patients
with AMD compared to unaffected controls (Wei et al., 2012).
In addition, this report also showed that ILRC17 is overex-
pressed in the macula of AMD patients (Wei et al., 2012).1528 Cell Reports 6, 1527–1535, December 26, 2013 ª2013 The AutTo further investigate the role of epigenetic modifications on
gene regulation in AMD, we explored the methylation status of
the CpG rich region within the IL17RC promoter in peripheral
blood obtained from three independent cohorts of AMD patients
and unaffected controls: theMichigan subset of the AMD-MMAP
cohort, a Baltimore cohort and an Australian cohort. Initially, we
examined the methylation status of probes adjacent to IL17RC
from our ongoing genome-wide methylation analysis (using the
Illumina Infinium Human Methylation450 [450K] Bead Array) in
the Michigan AMD-MMAP cohort, comparing the peripheral
whole blood profiles in patients with diagnosed AMD (either
geographic atrophy [GA, dry AMD] or choroidal neovasculariza-
tion [NV, wet AMD]) to that of healthy controls. We then specif-
ically targeted the identical cytosine residues reported to be
differentially methylated (Wei et al., 2012) and analyzed the
methylation status of these residues in the Baltimore and Austra-
lian cohorts by direct bisulfite pyrosequencing and the methyl-
ation-sensitive, restriction-enzyme-based EpiTect Methyl II
PCR assay. Combined, our analysis of the three cohorts re-
vealed no evidence of disease association at this locus, with all
peripheral whole blood samples examined showing very low
levels of IL17RC promoter methylation. Hypomethylation at
IL17RC was also evident in peripheral blood mononuclear cells
(PBMCs) and granulocytes from control subjects with no evi-
dence of any change in AMD individuals. Our results demon-
strate that IL17RC hypomethylation in peripheral blood is
unlikely to serve as a clinically useful biomarker for AMD.
RESULTS
Illumina Infinium Human Methylation450 Bead Arrays
We performed an epigenome-wide association study (EWAS) on
peripheral whole blood from 100 AMD (GA and NV) case-control
trios (a subset of the Michigan AMD-MMAP cohort; dbGaP
phs000182) using the HM450 platform (V.F.O., A.E.J., K.E.B.,
M.O., J.R.H., A.S., J.Q., D.J.Z., and S.L.M., unpublished data).
Each trio (one patient with bilateral GA, one patient with bilateral
NV, one control) was matched for sex and for age (<1 year differ-
ence among the three individuals in each trio). The sample group
comprised 63% females, with a mean ± SD age of 79.3 ±
5.6 years. There was no significant difference in age between
the AMD (79.3 ± 5.5 years, n = 200) and control (79.3 ± 5.7, n =
100) groups (p = 0.93; unpaired Student’s t test). We utilized
this data set to examine the methylation of IL17RC in a cohort in-
dependent of that previously described (Wei et al., 2012). The
Illumina Infinium Human Methylation450 (450K) array included
35 probes located within 26 kb downstream and 8 kb upstream
of the IL17RC transcription start site (TSS; chr3:9958758; hg19)
(Table S1). The region interrogated using the Methyl-Profiler
assay assesses methylation within a 80 bp region (chr3:
9957001-9957080), 1.7 kb upstream from the IL17RC TSS
(Wei et al., 2012) and within the region covered interrogated in
our analysis. One probe on the 450K array was contained within
this region (probe cg19148440), located at chr3:9957031. This
probe did not show a statistically significant difference in DNA
methylation levels between the AMDandcontrol groups (Figure 1
and Table S1). Specifically, the AMD population (n = 199) had
a mean methylation level of 7.9% and the control populationhors
Figure 2. Comparison of DNA Methylation
Levels within the IL17RC Promoter in
Patients with AMD and Age- and Gender-
Matched Controls with No Current, Past,
or Family History of Any Ocular Disease
(A) DNA methylation of IL17RC in peripheral blood
DNA. Each data point represents the mean
percentage methylation within individual AMD
(circles; Baltimore n = 39, Australia n = 100) and
control (squares; Baltimore n = 23, Australia
n = 116) subjects. Methylation was measured
across 33 CpG sites (Baltimore cohort) or 8 CpG
sites (Australian cohort), which overlapped the
region previously interrogated (Wei et al., 2012).
All samples showed <6% methylation by bisulfite
pyrosequencing. The Baltimore cohort indicated
small yet significant hypomethylation of the con-
trol cases (p = < 0.0001). There was no significant
difference in mean methylation between cases
and controls in the Australian cohort (p = 0.30).
Note the split y axis. See also Table S2.
(B and C) Comparison of DNA methylation levels
within the IL17RC promoter in donor retina/
RPE tissue from individuals with AMD and con-
trols with no reported history or pathological
evidence of ocular disease. Each data point
represents the mean percentage methylation
within the individual tissue samples from AMD
(circles) and control (squares) donors overlapping
the region interrogated by Wei et al. (Wei et al.,
2012). (B) Methylation was measured across
19 CpG sites in retina from AMD (n = 9) and control
(n = 6) donors. (C) Methylation was measured
across 33 CpG sites in RPE/choroid from AMD
(n = 3) and control (n = 3) donors. Hypomethylation
was observed in both tissues at all CpG sites
examined.(n = 99) had a mean methylation level of 6.9% (p = 0.18) (Fig-
ure 1). A vast majority of the peripheral whole blood samples
showed low levels of methylation of < 10%, with only seven
samples (one case and six controls of 198 total) having
methylation levels >20% (Figure S1). Although 5 out of the
35 probes within 34 kb of IL17RC reached marginal statistical
significance prior to multiple testing correction (p < 0.05),
these differences had an absolute difference in methylation
levels of <1% between the case and control groups and repre-
sented a mix of both relative hypo- and hypermethylation of
IL17RC in AMD cases; the remaining 30 probes did not show a
difference in methylation between the AMD cases and controls
(Table S1).
Pyrosequencing of the IL17RC Promoter Region in Two
Independent Cohorts
To explore the IL17RC methylation status in more detail, DNA
methylation was measured using bisulfite pyrosequencing from
samples derived from peripheral blood collected at Johns
Hopkins University, Baltimore. The final cohort comprised
24 patients with GA (11 females), 15 patients with NV (10
females), and 23 controls (13 females). There was no significant
age difference between the Baltimore control population (80.0 ±Cell Re7.4 years, mean ± SD; n = 23) and the Baltimore AMD population
(76.6 ± 10.2 years; n = 39; unpaired Student’s t test, p = 0.17).
A total of 33 CpG sites were interrogated encompassing the
region chr3:9956901-9957135, specifically including the region
identified as hypomethylated in AMD (Wei et al., 2012). In
accordance with the 450K data, both the AMD and the control
samples from the Baltimore cohort showed very low levels of
methylation overall (controls: 1.55% ± 0.07% [SEM], n = 23;
AMD: 2.11% ± 0.08%, n = 39) (Figure 2). This lack of methylation
at the promoter region of IL17RC differed from the levels
previously observed in peripheral blood mononuclear cells of
30% in AMD cases and 60% in controls (calculated as the
average of 96 control individuals and 202 individuals with AMD
from Table S4 in Wei et al., 2012). We observed no significant
hypomethylation of the promoter region of IL17RC in AMD
cases relative to controls at any of the 33 CpG sites interrogated
(Table S2). In fact, a slight but significant relative hypermethyla-
tion of AMD samples was observed (unpaired Student’s t test,
p < 0.001).
Given that comprehensive analysis in the Baltimore cohort
revealed consistent hypomethylation of the IL17RC promoter
in both AMD cases and normal controls, a second, independent
cohort from Australia was examined. Bisulfite pyrosequencingports 6, 1527–1535, December 26, 2013 ª2013 The Authors 1529
Figure 3. EpiTect Methyl II PCR Assay Results for the IL17RC Pro-
moter CpG Island in Peripheral Blood from a Subset of the Baltimore
Cohort
Each data point represents the percentage methylation from AMD (circles,
n = 20) and control (squares, n = 10) subjects at chr3:9956961-9957116 (hg19).
Data are plotted as the percentage of methylated DNA relative to the input. All
samples showed hypomethylation by this assay. There was no significant
difference in mean methylation between cases and controls using the EpiTect
Methyl II PCR assay for IL17RC (p = 0.34). See also Table S3.was performed on 100 AMD patients and 118 controls (Fig-
ure 2A). The mean age of the AMD patients (61 females) was
72.1 ± 6.3 years and of the controls (54 females) 71.0 ± 7.8 years
(Student’s t test, p = 0.25). Following bisulfite pyrosequencing of
eight CpG sites within the previously interrogated region
(chr3:9957024-9957056) (Wei et al., 2012), we did not detect
any significance differences in the mean methylation in AMD
patients (1.66% ± 0.06%, n = 100) compared to controls
(1.75% ± 0.06%, n = 118; p = 0.30). The bisulfite pyrosequencing
results indicated low levels of methylation (<6%) in all samples
and were consistent with the results from the Baltimore cohort
(Figure 2A). Only one individual (an AMD case) showed mildly
elevated methylation (16%) of a CpG site (chr3:9957047) relative
to the remainder of the cohort (Table S2).
Pyrosequencing of the IL17RC Promoter Region in
Ocular Tissue
Retina samples were obtained from nine individuals with AMD
(six men, 87.8 ± 5.8 years [mean age ± SD]; three women,
91.7 ± 0.6 years) and six controls (one man, 91 years; five
women, 88.4 ± 3.6 years). Retinal pigment epithelium (RPE) sam-
ples were obtained from three AMD (three men, 86.3 ± 8.0 years)
and three control (three men, 85.3 ± 5.5 years) donors. Bisulfite
pyrosequencing was performed on the region interrogated by
Wei et al. (2012), which showed low levels of methylation
(<6%) in all samples examined (Figures 2B and 2C). There was
no significant difference in the mean methylation of the retina
samples between the control (4.23% ± 0.51%, n = 6) and AMD
(3.49% ± 0.41%, n = 9; p = 0.28, Student’s t test) groups. The
RPE samples also showed a lack of methylation and no differ-
ence between the control (1.68% ± 0.08%, n = 3) and AMD
(1.69% ± 0.03%, n = 3; p = 0.88) donors. The level of methylation
within the ocular tissue samples was consistent with that
observed in peripheral blood (Figure 2A).1530 Cell Reports 6, 1527–1535, December 26, 2013 ª2013 The AutEpiTect Methyl II PCR Assay of IL17RC Promoter
Methylation in the Baltimore Samples
To determine whether the difference in overall peripheral blood
methylation levels resulted from technical or biological differ-
ences, the commercial EpiTect Methyl II PCR assay for IL17RC
(Qiagen) was performed on a subset of age/sex-matched Balti-
more samples (AMD n = 20, 12 women; controls n = 10, six
women). There was no significant age difference between the
AMDsamples (78.2 ± 5.7 years;mean ±SD) and the control sam-
ples (77.9 ± 6.2 years; unpaired Student’s t test p = 0.89). This
assay measures the amount of methylated DNA in a 156 bp
region centered around chr3:9957039 using methylation-sensi-
tive and methylation-dependent restriction digests followed by
quantitative PCR (qPCR) as utilized previously (Wei et al.,
2012). We did not detect any differences in the percentage of
methylated DNA between the AMD (0.10% ± 0.05 [SEM]) and
control groups (0.17% ± 0.03%; p = 0.34; unpaired Student’s
t test) using this restriction-enzyme-based approach (Figure 3).
Furthermore, all samples examined showed <1% methylated
DNA using the EpiTect Methyl II PCR Assay for IL17RC. These
results were entirely consistent with our bisulfite pyrosequencing
data from this region. Incomplete digest by the methylation-
dependent enzyme was excluded as a potentially confounding
factor in the observation of hypomethylation by the inclusion of
the methylation-dependent control assay (Table S3).
Comparison of IL17RC Promoter Methylation between
PBMCs and Granulocytes
Given that PBMCs were investigated previously (Wei et al.,
2012), we sought to directly compare the methylation profile of
the IL17RC promoter region between PBMCs, granulocytes
and whole blood. Additionally, given that hypermethylation of
this region was previously identified in individuals without
AMD, we analyzed fresh samples from elderly control subjects
(n = 18). Bisulfite pyrosequencing of the IL17RC promoter re-
vealed hypomethylation of all individuals and cell populations
examined (Figure 4 and Table S4). While there was a significant
difference in mean percentage methylation among the PBMCs
(2.34% ± 0.16% [SEM]), granulocytes (1.71% ± 0.05%), and
whole blood (1.90% ± 0.05) (F2,17 = 13.92, p = 0.0006), the overall
methylation levels were low and are likely to be below the sensi-
tivity level of the pyrosequencing assay. No significant cellular
heterogeneity or cell-type-specific DNA methylation differences
potentially accounting for the discrepancy with the previously
published results could be identified at this locus.
DISCUSSION
A recent study reported hypomethylation of the IL17RC pro-
moter in PBMCs of AMD patients and a corresponding increase
in IL17RC gene expression in macular tissue of AMD cadaver
eyes (Wei et al., 2012). These results suggested IL17RC as a
potential biomarker for AMD diagnosis. To explore these re-
ported findings further, we examined the IL17RC promoter
region in circulating peripheral whole blood (leukocytes), using
three distinct techniques in three independent cohorts (summa-
rized in Table 1). Our results indicate that IL17RC is essentially
unmethylated in peripheral blood of both AMD and controlhors
Figure 4. Comparison of DNA Methylation Levels within the IL17RC
Promoter in Ficoll-Separated PBMCs and Granulocytes or Unsorted
Whole Blood from Patients with No Current or Past Ocular Disease
or Known Family History of AMD
Methylation was measured in 18 individuals across 14 CpG sites encom-
passing the region interrogated by Wei et al. (Wei et al., 2012). Each data point
represents the mean percentage methylation across this region with the lines
joining samples obtained from the same individual. No individual CpG sites
had >6% methylation by bisulfite pyrosequencing in any sample. There was a
small but significant difference in methylation between the cell populations
(p < 0.001). Note the split y axis.
See also Table S4.populations and that themethylation level of IL17RC is unlikely to
serve as a useful clinical biomarker of AMD.
Using two methods that interrogate methylation changes at
individual CpG dinucleotides (bisulfite pyrosequencing and
the 450K methylation array), we were unable to reproduce the
high percentage of methylated DNA (60%) in the IL17RC pro-
moter previously seen in control individuals (Wei et al., 2012).
To ensure that our findings did not reflect a population-specific
effect, we bisulfite pyrosequenced the region in a second inde-
pendent cohort from Australia, confirming a low level of methyl-
ation in both the AMD and control peripheral whole blood
samples (1.7% and 1.8%, respectively). Unexpectedly, the dif-
ference in our results is not due to a difference in the clinical
definition of the AMD phenotype, as our results differed with
respect to the unaffected control population, which contained
over two and a half times the number of controls compared
with the Wei et al. study (263 versus 96) (Wei et al., 2012).
The average age of our Michigan AMD-MMAP control individ-
uals is 79 years and that of our Baltimore controls is 80 years.
Although these values are not statistically different from the
average age of our AMD patients (79 years and 75 years,
respectively; p = 0.93), these individuals are slightly older
than the average control subjects (70 years) in the study by
Wei et al. (2012). However, it seems unlikely that the younger
age in the National Eye Institute cohort (Wei et al., 2012) alone
explains the higher level of methylation, as the average age of
controls within the Australian cohort is 71 years and each of
these individuals showed a methylation level of <6%. In the
previous report, control individuals had methylation levels
covering the entire spectrum of 0%–100% methylation (Wei
et al., 2012).Cell ReThe previous study (Wei et al., 2012) used an enzymatic
method to measure methylation that relies on effective digestion
of high-quality genomic DNA with methylation-dependent and
methylation-independent restriction enzymes (Methyl-Profiler).
It is designed to detect global methylation changes, rather than
site-specific methylation changes. To verify that our observation
did not result from differences in the methylation analysis
techniques, we performed the same restriction enzyme-based
analysis using the rebranded EpiTect Methyl Restriction kit (pre-
viously Methyl-Profiler) followed by the EpiTect Methyl II PCR
Assay for IL17RC on a subset of the Baltimore peripheral whole
blood samples. Using the commercially available IL17RC
primers, we again found that the percentage of methylated
DNA was very low in both cases and controls. Wei et al. used
primers that differed from those provided in the commercially
available EpiTect Methyl II PCR assay (see the Supplemental
Information in Wei et al., 2012), although the same (but not iden-
tical) genetic location was targeted for amplification and interro-
gation by the enzyme digestion. This technique is susceptible to
giving falsely high methylation measurements if incomplete
digestion of unmethylated DNA with the methylation-dependent
enzyme occurs. Sodium bisulfite conversion-basedmethods are
widely considered the gold standard for measuring DNAmethyl-
ation and enable quantitative measurements from a single CpG
site. Both of the techniques utilized in our study (Illumina Infinium
Human Methylation450 [450K] Bead Array and bisulfite pyrose-
quencing) are based on bisulfite-converted DNA.
Cellular heterogeneity is widely regarded as a potential con-
founding factor in case-control studies aimed at linking epige-
netic disruption to specific phenotypes. As such, we considered
this as another potential explanation for the discrepant findings.
Our collection of peripheral blood samples contained the entire
leukocyte (white blood cell) component of blood, unlike the
PBMC fraction previously interrogated, which lacks polymor-
phonuclear (granulocyte) cells (Wei et al., 2012). To address
this issue, we isolated PBMCs and granulocytes from peripheral
blood and compared the methylation status of 14 previously
analyzed CpG sites in each cell type as well as in peripheral
whole blood from the same control individual. All three cell pop-
ulations had methylation levels of <5%, thereby eliminating the
possibility that cell composition differences could account for
the discrepancy. As Ficoll-separated samples were processed
within 2 hr of phlebotomy and still yielded lowmethylation levels,
we also excluded the possibility that processing time may have
altered the DNA methylation in our cohorts.
Genes expressed in many different tissues typically have an
unmethylated CpG island upstream from their TSS, and methyl-
ation of such islands is strongly associated with decreased gene
expression (Jones, 2012). The region in question is 1,700 bp
upstream from the IL17RC TSS and located in a CpG island.
Consistent with our finding of a low methylation level is the fact
that IL17RC is widely expressed in a range of human tissues
(Haudenschild et al., 2002). We have shown comparably low
levels of methylation at Rho and Rbp3 in expressing cells, while
nonexpressing cells showed > 60% methylation (Merbs et al.,
2012). Many factors other than DNA methylation could explain
the expression difference between AMD patients and controls
seen by Wei et al. Our bisulfite pyrosequencing also indicatedports 6, 1527–1535, December 26, 2013 ª2013 The Authors 1531
Table 1. Summary of Our Present IL17RC Promoter Methylation Results in Comparison to the Previously Published AMD Data Set
Cohort Technique
Target Chromosome Location
(hg19)
Mean Methylation Level (%)
Case Control
Michigan AMD-MMAP Illumina Infinium Human Methylation450 (450K) Bead
Arrays
chr3:9957031 7.9 6.9
Baltimore bisulfite pyrosequencing chr3:9956901-9957135 2.1 1.6
methylation-sensitive qPCR (EpiTect Methyl II PCR
assay)
chr3:9956961-9957117 0.1a 0.2a
Australia bisulfite pyrosequencing chr3:9957024-9957056 1.7 1.8
National Eye Institute
(Wei et al., 2012)
methylation-sensitive qPCR (Methyl-Profiler) chr3:9957001-9957080 30.0a 60.0b
aPercentage of methylated DNA relative to input.
bCalculated from Table S4 in Wei et al. (2012).that the IL17RC promoter is lowly methylated in the retina and
RPE of both AMD cases and controls. Wei et al. previously re-
ported increased expression of IL17RC in the macula of patients
with AMD. While our data do not dispute these findings, they do
suggest that the regulation of IL17RC expression is unlikely to be
the result of differential methylation of the promoter region in
AMD individuals. While we believe that the level of IL17RC
DNA methylation is not a good marker for AMD, it is possible
that the expression and protein levels of IL17RC might still be
useful biomarkers.
In summary, our comprehensive analysis of DNA methylation
of the IL17RC promoter in peripheral blood samples from three
independent AMD cohorts was unable to replicate the reported
differential methylation using three different techniques, in-
cluding the gold standard of bisulfite pyrosequencing. Examina-
tion of retinal tissue also indicated low levels of methylation in all
samples examined. Furthermore, we observed very little methyl-
ation in all of our control samples, compared to the relatively high
levels previously reported. Consistent with our finding of a low
methylation level is the fact that IL17RC is widely expressed in
a range of human tissues (Haudenschild et al., 2002). The differ-
ence in the percentage of methylation previously reported is sur-
prisingly large. A 30%methylation difference between cases and
controls is much greater than methylation differences typically
seen in other complex diseases such as autism (7%–16% in
brain samples; Ladd-Acosta et al., 2013) and obesity (1%–
16% in blood; Alme´n et al., 2012) and is also higher than many
methylation differences seen between cancer and normal tis-
sues (Hansen et al., 2011; Irizarry et al., 2009). Our findings sug-
gest that hypomethylation within the IL17RC gene promoter is
not suitable for use as a clinical biomarker of AMD and highlight
the need for considerable replication of epigenetic association
studies prior to clinical application.
EXPERIMENTAL PROCEDURES
Ethical Approval
All aspects of this project were conducted in accordance with the principles of
the Declaration of Helsinki, with informed consent being obtained from all par-
ticipants. This project was approved by the Human Research Ethics Commit-
tees of the Royal Victorian Eye and Ear Hospital and the University of Western
Australia and with Institutional Review Board approval from the Johns Hopkins
University School of Medicine.1532 Cell Reports 6, 1527–1535, December 26, 2013 ª2013 The AutIllumina Infinium Human Methylation450 Bead Array
The 450K methylation array is widely accepted as a robust platform to assess
DNA methylation, showing a high concordance with bisulfite pyrosequencing
(r > 0.80) (Roessler et al., 2012). DNA samples from peripheral blood of 298
age- and sex-matched samples (comprising 100 bilateral GA, 99 bilateral
NV, and 99 controls) were obtained from a subset of the Michigan patients
from the Age-related Macular Degeneration Michigan, Mayo, AREDS, Penn-
sylvania (AMD-MMAP) study cohort (dbGaP: phs000182). DNA was extracted
from whole blood using the Puregene Blood Core Kit C (Qiagen). Both the
AMD and the control groups were 63% female, with a mean ± SD age of
79.3 ± 5.7 years in the AMD group and 79.3 ± 5.5 years in the control group.
All samples were derived from the Kellogg Eye Center (KEC) at the University
of Michigan (Chen et al., 2010). From the original KEC cohort, those patients
with bilateral GA or NV were selected. Control patients were examined and
accepted if they had small drusen and pigment changes in one eye only with
no family history of AMD. All cases and controls were R60 years of age.
DNA samples (1.3 mg) were processed for the HM450 platform (Illumina) at
the Center for Inherited Disease Research (CIDR; Johns Hopkins University)
as per the manufacturers’ protocols. All matched samples (GA-NV-control)
were run within a single BeadChip array.
Illumina Infinium Human Methylation450 Bead Array Data
Preprocessing
We normalized the intensity data using a modified version of quantile normal-
ization in the minfi Bioconductor package (http http://bioconductor.org/
packages/devel/bioc/html/minfi.html/), which, briefly, forces the distribution
of type I and type II probes on the Illumina 450K microarray to be the same.
Quantile normalization is performed on the type II probes and then interpo-
lated to a reference distribution to which the type I probes are normalized.
This normalization is performed separately on the methylated (M) and unme-
thylated (U) channel intensities. The logit-transformed DNA methylation
(DNAm) is y = log2(M/U), and the proportion methylation (‘‘beta’’ scale, as
reported by Illumina) can be obtained by: 2y/(1 + 2y). The ‘‘beta’’ values for
probes in and around IL17RC (n = 35) were selected for subsequent statistical
analyses.
Sample Selection from the Baltimore Cohort
DNA samples derived from peripheral whole blood were obtained from a
cohort collected at Johns Hopkins University in Baltimore as previously
described (Yang et al., 2008, 2010). In short, diagnosis of advanced AMD
was based on the presence of GA or CNV (equivalent to AREDS category
4 or 5). Controls were identified as >60 years of age and having fewer than
five small drusen (<63 mm) and no RPE abnormalities. The final cohort
comprised 24 patients with GA (mean ±SD age at interview of 78.5 ± 7.6 years;
13men and 11 women; European = 24), 15 patients with NV (73.7 ± 13.1 years;
five men and ten women; European = 14, Ashkenazi Jew = 1), and 23 controls
(80.0 ± 7.4 years; 10 men and 13 women; European = 23). Genomic DNA was
isolated from peripheral whole blood using Puregene Blood Kit chemistryhors
on an Autopure LS automated DNA purification instrument (Qiagen). DNA con-
centrations are determined by spectrophotometry using a DU 530 Life Science
UV/Vis Spectrophotometer (Beckman Coulter).
Sample Collection in an Australian Cohort
Patients with AMD were recruited from ophthalmology clinics at Launceston
Eye Institute, Australia. The clinical criteria for the diagnosis of AMD included
the presence of extensive drusen and associated pigmentary abnormalities of
the RPE layer or evidence of advanced disease by presence of GA or NV. Age-
and sex-matched controls were recruited from adjunct genetic studies. All
control subjects underwent a comprehensive examination including fundus
photography as well as macular assessment using optical coherence tomog-
raphy. To be included as a control, subjects required no evidence of
ophthalmic pathology as well as no prior or known family history of ocular dis-
ease. In total, we recruited 100 patients with AMD and 120 age-matched indi-
viduals with no signs of AMD. Two control samples failed DNA extraction from
whole blood. All participants were of reported Northern European ancestry.
The mean ± SD age of the AMD patients and controls (passing whole blood
DNA quality control) was 72.1 ± 6.3 years and 71.0 ± 7.8 years, respectively.
A total of 39% of the AMD patients and 54% of controls were male. Approxi-
mately 20 ml EDTA peripheral whole blood was collected via venipuncture
from all participants and genomic DNA was extracted from circulating leuko-
cytes by the QIAcube platform (Qiagen) through the facilities at the Western
Australian DNA Bank.
Bisulfite Pyrosequencing of the IL17RC Promoter
Bisulfite pyrosequencing is widely considered the gold-standard approach for
quantitatively measuring DNA methylation across targeted regions (<400 bp)
of the genome. Pyrosequencing assays were designed using algorithms built
into the PyroMark Assay Design Software (version 2.0.1; Qiagen). Briefly,
primers designed to target specific CpG sites within the IL17RC promoter
were chosen from a list generated by the software on the basis of the
algorithms’ predicted assay quality. Genomic DNA (500 ng) was bisulfite con-
verted using the EZ DNA Methylation Gold kit (Zymo Research) according to
the manufacturer’s instructions. Following bisulfite treatment, all previously
unmethylated cytosine residues are converted to uracil, whereas methylated
cytosine residues remain unconverted. DNA containing the segment of the
IL17RC promoter analyzed by Wei and colleagues (Wei et al., 2012) was
amplified from the bisulfite-treated DNA using PCR primer set 1 (Australian
samples) and PCR primer sets 1 and 3 (Baltimore samples) as shown in
Table S5.
PCR products were bound to Streptavidin Sepharose High Performance
beads (GE Healthcare) and a single-strand template was isolated using the
Pyrosequencing Vacuum Prep Tool (Qiagen). The beads were transferred
to an optically clear, 24-well sequencing plate in 0.3 mM of the sequencing
primer. Serial pyrosequencing was performed where multiple sequencing
primers were contained within a single PCR amplicon (Tost et al., 2006;
Tost and Gut, 2007). Pyrosequencing was performed on a PyroMark 24
Pyrosequencing System (Qiagen) as per the manufacturer’s instructions.
Data were analyzed on the PyroMark Q24 software (Qiagen). This software
calculates the C peak as a percentage of the T plus C peak at each CpG
site taking into account sequence length and signal strength. The mean
methylation for each individual was calculated. Initially, eight CpG sites
overlapping the region specifically targeted previously (Wei et al., 2012)
were investigated in the Baltimore and Australian cohorts. To further
explore additional regions at the locus, an additional 25 CpGs were
sequenced in the Baltimore cohort alone. An unpaired Student’s t test was
used to compare the methylation difference between the matched case-
control groups.
Collection of Retina/RPE from Cadaver Eyes
Cadaver eyes with a known medical history of AMD and unaffected controls
were obtained from the National Disease Research Interchange (NDRI) with
ethical approval from the Johns Hopkins University School of Medicine
IRB. In brief, the anterior segment was removed, along with the pupil and
lens. Four cuts were made down the eye cup to expose the macula. The
flower-cut eye cup was exposed to a sucrose gradient as previouslyCell Redescribed (Hackler et al., 2012). The macula and optic nerve head were
removed by 6 mm biopsy punches, and the remaining peripheral retina
and RPE/choroid were stored at 80C. AMD was confirmed by assessment
of macula photos taken prior to the sucrose treatment. DNA was extracted
from the retina/RPE using the DNEasy Blood & Tissue kit (Qiagen) as per
the manufacturer’s protocol. Retina samples were obtained from nine
AMD (six men, 87.8 ± 5.8 years [mean age ± SD]; three women, 91.7 ± 0.6
years) and six controls (one man, 91 years; five women, 88.4 ± 3.6 years).
RPE samples were obtained from three AMD (three men, 86.3 ± 8.0 years)
and three control (three men, 85.3 ± 5.5 years) donors. The bisulfite
conversion and subsequent pyrosequencing of IL17RC was performed as
described above.
Application of the EpiTect Methyl II PCR Assay for IL17RC to
Baltimore Samples
DNA samples from ten age/sex-matched GA/NV/control trios (derived from
peripheral whole blood) were selected from the Baltimore samples previously
used for bisulfite pyrosequencing. The mean age of the subset of Baltimore
AMD samples was 78.2 ± 5.7 years (mean ± SD; n = 20, 12 women). The
mean age of the Baltimore controls subgroup was 77.9 ± 6.2 years (n = 10,
of whom six were female). The Methyl-Profiler restriction assay Kit (MeA-01,
SABiosciences) has been rebranded as the EpiTect Methyl II Restriction Kit
(335452, Qiagen). The EpiTect Methyl II restriction digest was set up according
to the manufacturer’s protocol. Briefly, 230 ng of DNA was used in each of the
following restriction enzyme digest reactions: (1) methylation-sensitive, (2)
methylation-dependent, (3) methylation-sensitive and methylation-dependent
double digest, or (4) mock digest. qPCR was performed as per the
manufacturer’s protocol, using commercially available primers for IL17RC
(EPHS110029-1A, Qiagen) in RT2 SYBR Green qPCR Mastermix (330500,
Qiagen) on a CFX96 real-time PCR machine (Bio-Rad). The commercially
validated IL17RC EpiTect Methyl II PCR primers interrogated methylated
DNA in a 156 bp region centered on chr3:9957039, targeting the same region
reported by Wei et al., (2012). Methylation-sensitive (EPHS115450-1A) and
methylation-dependent (EPHS115451-1A) digest control assays were per-
formed on a subset (n = 7) of samples. Samples were analyzed as recommen-
ded by the manufacturer (http://www.sabiosciences.com/dna_methylation_
data_analysis.php/).
Cell Separation for Comparison of PBMCs and Granulocyte Cell
IL17RC Promoter Methylation Status
PBMCs and granulocytes were isolated from whole blood collected from
20 Australian controls (a subset of those described above; mean age
82 years, range 77–90 years, 65% male) using Ficoll-Plaque Premium (GE
Healthcare Life Sciences) as per the manufacturer’s protocol. Blood
samples were all processed within 2 hr of phlebotomy. The granulocyte
fraction was extracted from the bottom of the tubes, with the PBMC fraction
being extracted from the serum/medium boundary. Genomic DNA isolated
from each cell type was bisulfite treated as described above. Two samples
failed DNA extraction from whole blood. The methylation status of 14 previ-
ously analyzed CpG sites within the IL17RC promoter was compared be-
tween PBMCs, granulocytes (polymorphonuclear leukocytes), and unsorted
whole blood using bisulfite pyrosequencing primer sets 1 and 2 (Table S5).
Groups of paired measurements were compared using repeated-measures
ANOVA.
SUPPLEMENTAL INFORMATION
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